Is MacroGenics Stock a Good Investment?
MacroGenics Investment Advice | MGNX |
- Examine MacroGenics' financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research MacroGenics' leadership team and their track record. Good management can help MacroGenics navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Biotechnology space and any emerging trends that could impact MacroGenics' business and its evolving consumer preferences.
- Compare MacroGenics' performance and market position to its competitors. Analyze how MacroGenics is positioned in terms of product offerings, innovation, and market share.
- Check if MacroGenics pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about MacroGenics' stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in MacroGenics stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if MacroGenics is a good investment.
Sell | Buy |
Strong Sell
Market Performance | Insignificant | Details | |
Volatility | Moderately volatile | Details | |
Hype Condition | Under hyped | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Buy | Details | |
Financial Strenth (F Score) | Poor | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine MacroGenics Stock
Researching MacroGenics' stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 94.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.88. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. MacroGenics has Price/Earnings To Growth (PEG) ratio of 0.01. The entity recorded a loss per share of 1.61. The firm had not issued any dividends in recent years.
To determine if MacroGenics is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding MacroGenics' research are outlined below:
| MacroGenics had very high historical volatility over the last 90 days | |
| MacroGenics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the previous year's revenue of 58.75 M. Net Loss for the year was (9.06 M) with loss before overhead, payroll, taxes, and interest of (62.47 M). | |
| MacroGenics currently holds about 133.74 M in cash with (78.2 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 2.18. | |
| MacroGenics has a poor financial position based on the latest SEC disclosures | |
| Over 94.0% of the company shares are owned by institutional investors | |
| Latest headline from finance.yahoo.com: Breast Cancer Therapeutics Global Market Research 2024 Advancements in Targeted and Immunotherapies Revolutionize Treatment - Forecasts to 2030 |
MacroGenics uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in MacroGenics. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to MacroGenics' previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 20th of March 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 20th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact MacroGenics' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises MacroGenics' investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2014-05-06 | 2014-03-31 | -0.08 | -0.12 | -0.04 | 50 | ||
2023-03-15 | 2022-12-31 | 0.1 | 0.21 | 0.11 | 110 | ||
2020-05-05 | 2020-03-31 | -1.02 | -0.91 | 0.11 | 10 | ||
2017-05-03 | 2017-03-31 | -0.97 | -1.08 | -0.11 | 11 | ||
2017-02-28 | 2016-12-31 | -0.89 | -1.0 | -0.11 | 12 | ||
2019-05-01 | 2019-03-31 | -0.86 | -0.99 | -0.13 | 15 | ||
2014-03-20 | 2013-12-31 | -0.27 | -0.14 | 0.13 | 48 | ||
2022-02-24 | 2021-12-31 | -0.81 | -0.95 | -0.14 | 17 |
Know MacroGenics' Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as MacroGenics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading MacroGenics backward and forwards among themselves. MacroGenics' institutional investor refers to the entity that pools money to purchase MacroGenics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Two Sigma Investments Llc | 2024-09-30 | 883.4 K | Dimensional Fund Advisors, Inc. | 2024-09-30 | 882.7 K | Vestal Point Capital Lp | 2024-09-30 | 830 K | Northern Trust Corp | 2024-09-30 | 702.8 K | Pinnacle Associates Inc | 2024-09-30 | 688 K | Connor Clark & Lunn Inv Mgmt Ltd | 2024-09-30 | 661.9 K | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 566.3 K | Charles Schwab Investment Management Inc | 2024-09-30 | 492.8 K | Jane Street Group Llc | 2024-06-30 | 487.2 K | Bellevue Group Ag | 2024-09-30 | 9.9 M | Armistice Capital, Llc | 2024-09-30 | 6.3 M |
MacroGenics' market capitalization trends
The company currently falls under 'Small-Cap' category with a current market capitalization of 231.6 M.Market Cap |
|
MacroGenics' profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.03) | (0.03) | |
| Return On Capital Employed | (0.69) | (0.66) | |
| Return On Assets | (0.03) | (0.03) | |
| Return On Equity | (0.06) | (0.06) |
Determining MacroGenics' profitability involves analyzing its financial statements and using various financial metrics to determine if MacroGenics is a good buy. For example, gross profit margin measures MacroGenics' profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of MacroGenics' profitability and make more informed investment decisions.
Please note, the imprecision that can be found in MacroGenics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of MacroGenics. Check MacroGenics' Beneish M Score to see the likelihood of MacroGenics' management manipulating its earnings.
Evaluate MacroGenics' management efficiency
MacroGenics has return on total asset (ROA) of (0.2215) % which means that it has lost $0.2215 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6217) %, meaning that it created substantial loss on money invested by shareholders. MacroGenics' management efficiency ratios could be used to measure how well MacroGenics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to drop to -0.03 in 2024. Return On Capital Employed is likely to rise to -0.66 in 2024. At this time, MacroGenics' Other Current Assets are fairly stable compared to the past year. Net Tangible Assets is likely to rise to about 245.6 M in 2024, whereas Total Assets are likely to drop slightly above 287.5 M in 2024.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 2.46 | 2.34 | |
| Tangible Book Value Per Share | 2.46 | 2.34 | |
| Enterprise Value Over EBITDA | 262.16 | 275.27 | |
| Price Book Value Ratio | 3.90 | 4.10 | |
| Enterprise Value Multiple | 262.16 | 275.27 | |
| Price Fair Value | 3.90 | 4.10 | |
| Enterprise Value | 528.8 M | 475.5 M |
Leadership effectiveness at MacroGenics is a strong indicator of its financial stability. We analyze various metrics to provide insights into the stock's investment viability.
Beta 2.076 |
Basic technical analysis of MacroGenics Stock
As of the 3rd of December, MacroGenics secures the Mean Deviation of 3.3, risk adjusted performance of 0.0409, and Downside Deviation of 4.79. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of MacroGenics, as well as the relationship between them.MacroGenics' insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific MacroGenics insiders, such as employees or executives, is commonly permitted as long as it does not rely on MacroGenics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases MacroGenics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Koenig Scott over a month ago Disposition of 53265 shares by Koenig Scott of MacroGenics subject to Rule 16b-3 | ||
Koenig Scott over two months ago Acquisition by Koenig Scott of 374215 shares of MacroGenics subject to Rule 16b-3 | ||
Jeffrey Peters over three months ago Acquisition by Jeffrey Peters of 26250 shares of MacroGenics subject to Rule 16b-3 | ||
Jeffrey Peters over six months ago Acquisition by Jeffrey Peters of 13336 shares of MacroGenics subject to Rule 16b-3 | ||
Jeffrey Peters over six months ago Acquisition by Jeffrey Peters of 54376 shares of MacroGenics at 11.5 subject to Rule 16b-3 | ||
Jeffrey Peters over six months ago Disposition of 10875 shares by Jeffrey Peters of MacroGenics at 11.5 subject to Rule 16b-3 | ||
David Stump over a year ago Acquisition by David Stump of 19000 shares of MacroGenics subject to Rule 16b-3 |
MacroGenics' Outstanding Corporate Bonds
MacroGenics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. MacroGenics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most MacroGenics bonds can be classified according to their maturity, which is the date when MacroGenics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| Dana 575 percent Corp BondUS235822AB96 | View | |
| MQGAU 3052 03 MAR 36 Corp BondUS556079AD36 | View | |
| MQGAU 3624 03 JUN 30 Corp BondUS556079AC52 | View | |
| MQGAU 6798 18 JAN 33 Corp BondUS556079AF83 | View | |
| Boeing Co 2196 Corp BondUS097023DG73 | View | |
| MQGAU 23 22 JAN 25 Corp BondUS55608PBE34 | View | |
| MQGAU 5757067 21 MAR 25 Corp BondUS55608PBK93 | View | |
| MQGAU 3231 21 MAR 25 Corp BondUS55608PBJ21 | View |
Understand MacroGenics' technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing MacroGenics' various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0409 | |||
| Market Risk Adjusted Performance | 0.0805 | |||
| Mean Deviation | 3.3 | |||
| Semi Deviation | 4.5 | |||
| Downside Deviation | 4.79 | |||
| Coefficient Of Variation | 2335.27 | |||
| Standard Deviation | 4.28 | |||
| Variance | 18.34 | |||
| Information Ratio | 0.0138 | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.47) | |||
| Sortino Ratio | 0.0123 | |||
| Treynor Ratio | 0.0705 | |||
| Maximum Drawdown | 19.32 | |||
| Value At Risk | (7.01) | |||
| Potential Upside | 7.06 | |||
| Downside Variance | 22.93 | |||
| Semi Variance | 20.29 | |||
| Expected Short fall | (3.13) | |||
| Skewness | 0.0583 | |||
| Kurtosis | 0.1304 |
| Risk Adjusted Performance | 0.0409 | |||
| Market Risk Adjusted Performance | 0.0805 | |||
| Mean Deviation | 3.3 | |||
| Semi Deviation | 4.5 | |||
| Downside Deviation | 4.79 | |||
| Coefficient Of Variation | 2335.27 | |||
| Standard Deviation | 4.28 | |||
| Variance | 18.34 | |||
| Information Ratio | 0.0138 | |||
| Jensen Alpha | (0.11) | |||
| Total Risk Alpha | (0.47) | |||
| Sortino Ratio | 0.0123 | |||
| Treynor Ratio | 0.0705 | |||
| Maximum Drawdown | 19.32 | |||
| Value At Risk | (7.01) | |||
| Potential Upside | 7.06 | |||
| Downside Variance | 22.93 | |||
| Semi Variance | 20.29 | |||
| Expected Short fall | (3.13) | |||
| Skewness | 0.0583 | |||
| Kurtosis | 0.1304 |
Consider MacroGenics' intraday indicators
MacroGenics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of MacroGenics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
MacroGenics Corporate Filings
8K | 21st of November 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
13A | 20th of November 2024 The form used by investors holding more than 5% of a company's stock, to report their beneficial ownership pursuant to Rule 13d-1 or Rule 13d-2 under the Securities Exchange Act of 1934 | ViewVerify |
13A | 14th of November 2024 An amended filing to the original Schedule 13G | ViewVerify |
10Q | 5th of November 2024 Quarterly performance report mandated by Securities and Exchange Commission (SEC), to be filed by publicly traded corporations | ViewVerify |
MacroGenics Stock media impact
Far too much social signal, news, headlines, and media speculation about MacroGenics that are available to investors today. That information is available publicly through MacroGenics media outlets and privately through word of mouth or via MacroGenics internal channels. However, regardless of the origin, that massive amount of MacroGenics data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of MacroGenics news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of MacroGenics relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to MacroGenics' headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive MacroGenics alpha.
MacroGenics Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards MacroGenics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
MacroGenics Corporate Executives
Elected by the shareholders, the MacroGenics' board of directors comprises two types of representatives: MacroGenics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of MacroGenics. The board's role is to monitor MacroGenics' management team and ensure that shareholders' interests are well served. MacroGenics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, MacroGenics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| James Karrels | CFO, Sr. VP and Corporate Secretary | Profile |
Additional Tools for MacroGenics Stock Analysis
When running MacroGenics' price analysis, check to measure MacroGenics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MacroGenics is operating at the current time. Most of MacroGenics' value examination focuses on studying past and present price action to predict the probability of MacroGenics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MacroGenics' price. Additionally, you may evaluate how the addition of MacroGenics to your portfolios can decrease your overall portfolio volatility.